Testosterone in men with advanced liver disease: Abnormalities and implications

• Published in: Journal of gastroenterology and hepatology Vol. 30; no. 2; pp. 244 - 251
• Main Authors: Sinclair, Marie, Grossmann, Mathis, Gow, Paul J, Angus, Peter W
• Format: Journal Article
• Language: English
• Published: Australia Blackwell Publishing Ltd 01-02-2015
• Subjects: advanced liver disease; cirrhosis; Hormone Replacement Therapy; Humans; Liver Cirrhosis - drug therapy; Liver Cirrhosis - etiology; Liver Cirrhosis - metabolism; Male; Prognosis; sarcopenia; Severity of Illness Index; testosterone; Testosterone - blood; Testosterone - deficiency; Testosterone - physiology; Testosterone - therapeutic use; advanced liver disease; testosterone; cirrhosis; sarcopenia
• ISSN: 0815-9319; 1440-1746
• DOI: 10.1111/jgh.12695

Serum testosterone is reduced in up to 90% of men with cirrhosis, with levels falling as liver disease advances. Testosterone is an important anabolic hormone, with effects on muscle, bone, and hematopoiesis. Many of the features of advanced liver disease are similar to those seen in hypogonadal men, including sarcopenia, osteoporosis, gynecomastia, and low libido. However, the relative contribution of testosterone deficiency to the symptomatology of advanced liver disease has not been well established. More recently, it has been demonstrated that low testosterone in men with cirrhosis is associated with increased mortality, independent of the classically recognized prognostic factors, such as the Model for End‐Stage Liver Disease score. Only several small clinical trials have examined the role of testosterone therapy in men with cirrhosis, none of which have resolved the issue of whether or not testosterone is beneficial. However, in men with organic hypogonadism due to structural hypothalamic–pituitary–testicular axis disease, testosterone therapy has been shown to improve muscle mass and bone mineral density, increase hemoglobin, and reduce insulin resistance. Despite initial concerns linking testosterone with hepatocellular carcinoma, more recent data suggest that this risk has been overstated. There is, therefore, now a strong rationale to assess the efficacy and safety of testosterone therapy in cirrhosis in well‐designed randomized controlled trials.